<div id="readability-page-1"><div> <p>(RTTNews) - Korro Bio Inc. (KRRO), a biopharmaceutical company, has selected KRRO-111 as a development candidate for clinical advancement in the potential treatment of alpha-1 antitrypsin deficiency.</p> <p>Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that causes the depletion of protein in the lungs and liver, leading to pulmonary emphysema and/or hepatic cirrhosis. Affecting nearly 3.4 million people worldwide, the only current FDA-approved treatment for AATD is a once-weekly infusion of human plasma-derived AAT protein called augmentation therapy.</p> <p>KRRO-111 is a proprietary, GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells. </p> <p>In preclinical studies, the drug has demonstrated successful RNA-editing by more than 90% in cells, correcting AAT transcription in liver cells. In mice models, the production of circulating M-AAT protein indicates the potential to improve lung and liver manifestations of the disease.</p> <p>The company plans to present data on the preclinical validation of KRRO-111 as a candidate in treating AATD.</p> <p>KRRO is currently trading at $9.32, up 1.86%. </p> <p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p> </div></div>

KRRO

IBBQ

SBIO

LABU

<p>Korro Bio Inc. has chosen KRRO-111 as a candidate for clinical development to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting 3.4 million people globally. KRRO-111, a GaINAc-conjugate oligonucleotide, has shown over 90% RNA-editing success in preclinical studies. The company plans to present data on its preclinical validation. KRRO shares are currently trading at $9.32, up 1.86%.</p>

nasdaq

Korro Bio

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Nasdaq

Korro Bio To Advance KRRO-111 As Potential Treatment For AATD